German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros ($2.36 billion), Bloomberg said, citing people with knowledge of the matter.
Boehringer Ingelheim
Breaking News
Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.
California, US-based software developing company Accelrys has acquired Ireland-based software business Qumas in a deal valued at $50 million to expand its products expansion and client base.
Ben Venue Laboratories, a subsidiary of German Boehringer Ingelheim in the US, has engaged Bank of American Merill Lynch to advise it on a proposed sale of its sterile injectable drugs business.
Ben Venue was required by court to comply with good manufacturing standards set.
